GMTX News and Press, Gemini Therapeutics Inc. From 06/26/21

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. The S&P 500 closed the week at another record high, posting its best weekly performance since February, as investors bet that higher infl...

Gemini Therapeutics Inc. (NASDAQ:GMTX) traded at a new 52-week low today of $6.40. This new low was reached on above average trading volume as 660,000 shares traded hands, while the average 30-day volume is approximately 197,000 shares. Gemini Therapeutics Inc. (NASDAQ:GMTX) is currently...

sefa ozel/E+ via Getty Images Shares of Gemini Therapeutics (GMTX) are down 29% in afternoon trading after releasing initial data after the bell yesterday from a phase 2 trial of its geographic atrophy ("GA") secondary to age-related macular degeneration ("AMD") candidate ...

Gainers: Entera Bio (ENTX) +56%. Orphazyme (ORPH) +47%. Bellerophon Therapeutics (BLPH) +26%. HUTCHMED (HCM) +11%. Evaxion Biotech (EVAX) +8%.Losers: Gemini Therapeutics (GMTX) -32%. Second Sight Medical Products (EYES) -19%. Millendo Therapeutics (MLND) -17...

P_Wei/E+ via Getty Images Cassava Sciences is on recovery as B Riley lifts price target After a loss of ~13.5% yesterday, Cassava Sciences (SAVA) has recovered today rising ~2.6% in the premarket after B Riley Securities raised its price target to $111.00 from $78.00 per share imply...

Alex Potemkin/iStock Unreleased via Getty Images GlaxoSmithKline (GSK) received a boost in Wednesday's pre-market action on news that it plans to split off its consumer health unit. Traders also have their eyes on gambling names. Moves toward legalization in Canada have put Score Media and Ga...

Gemini Therapeutics (GMTX) -31% after initial data from mid-stage GEM103 AMD study.Second Sight Medical Products (EYES) -18% after secures $50M capital via equity raiseTorchlight Energy Resources (TRCH) -17%.Alfi (ALF) -16% stock pulls back from buyback-fueled ra...

– Biomarker results indicate GEM103’s ability to regulate complement and complement factor H therapeutic approach in geographic atrophy – – GEM103 continues to be well-tolerated and demonstrates a differentiated safety profile with no increased risk...

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to pa...

Gemini Therapeutics (GMTX): Q1 GAAP EPS of -$0.59 misses by $0.25.At March 31, 2021, Gemini held $185.0 million in cash, $9.2 million of principal outstanding debt and 43.0 million shares outstanding.Press Release For further details see: Gemini Therapeutics EPS misses by $0.25